chidamide
Showing 1 - 25 of 63
Leukemia, Myeloid, Acute Trial in Chengdu (Chidamide)
Recruiting
- Leukemia, Myeloid, Acute
- Chidamide
-
Chengdu, Sichuan, ChinaWest China Hospital of Sichuan University
Dec 27, 2022
Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype Trial in Guangzhou (Chidamide combined with CHOP,
Recruiting
- Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype
- Chidamide combined with CHOP
- Chidamide
-
Guangzhou, Guangdong, ChinaSun Yat-sen Universitiy Cancer Center, Sun Yat-Sen University
Oct 7, 2022
Breast Cancer Trial in Shanghai (Chidamide, Abemaciclib, Fulvestrant)
Recruiting
- Breast Cancer
- Chidamide
- +2 more
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Jul 31, 2022
Chidamide in Recurrent and Refractory Diffuse Large b
Enrolling by invitation
- Diffuse Large B-cell Lymphoma
- Chidamide
- +2 more
-
Suzhou, Jiangsu, ChinaSecond Affiliated Hospital of Soochow University
Jan 9, 2023
HR+/HER2- Advanced Breast Cancer Trial in Beijing (Dalpiciclib, Chidamide)
Not yet recruiting
- HR+/HER2- Advanced Breast Cancer
- Dalpiciclib
- Chidamide
-
Beijing, Beijing, ChinaThe Fifth Medical Center of PLA General Hospital
Oct 17, 2022
Non-hodgkin's Lymphoma Trial in Beijing (Chiauranib, Chidamide)
Completed
- Non-hodgkin's Lymphoma
- Chiauranib
- Chidamide
-
Beijing, Beijing, ChinaBeijing Cancer Hospital
Mar 7, 2022
Acute Myeloid Leukemia Trial in Nanjing (Chidamide, Cladribine)
Recruiting
- Acute Myeloid Leukemia
- Chidamide
- Cladribine
-
Nanjing, Jiangsu, ChinaDepartment of Hematology, Zhongda Hospital Southeast University,
Apr 23, 2022
Breast Cancer, Chemo Effect Trial in Beijing (Chidamide)
Recruiting
- Breast Cancer
- Chemotherapy Effect
- Chidamide
-
Beijing, Beijing, ChinaNational Cancer Center/National Clinical Research Center for Can
Feb 17, 2023
Hepatocellular Carcinoma (HCC) Trial in Taiwan (Chidamide, Regorafenib)
Recruiting
- Hepatocellular Carcinoma (HCC)
- Chidamide
- Regorafenib
-
Kaohsiung, Taiwan
- +4 more
Mar 14, 2023
Safety and Efficacy Trial in Suzhou (Chidamide)
Recruiting
- Safety and Efficacy
- Chidamide
-
Suzhou, Jiangsu, ChinaFirst Affiliated Hospital,Soochow University
Nov 30, 2021
Metastatic Colorectal Cancer Trial in New Taipei City (chidamide, celecoxib)
Recruiting
- Metastatic Colorectal Cancer
- chidamide
- celecoxib
-
New Taipei City, TaiwanTaipei Medical University Shuang Ho Hospital
Mar 4, 2022
HIV-1 Infection Trial in Kaohsiung City, Taiwan (UB-421, chidamide)
Recruiting
- HIV-1 Infection
- UB-421
- chidamide
-
Kaohsiung City, Taiwan, TaiwanKaohsiung Veterans General Hospital
May 12, 2022
Relapsed/Refractory Non-Hodgkin Lymphoma, Advanced Solid Tumors Trial in Beijing (Chidamide, Decitabine, Immune checkpoint
Recruiting
- Relapsed/Refractory Non-Hodgkin Lymphoma
- Advanced Solid Tumors
- Chidamide
- +2 more
-
Beijing, Beijing, ChinaBiotherapeutic Department, Chinese PLA General Hospital
Apr 8, 2022
Acute Monocytic Leukemia, Newly Diagnosed Trial in Suzhou (Chidamide, Azacitidine, Venetoclax)
Recruiting
- Acute Monocytic Leukemia
- Newly Diagnosed
- Chidamide
- +2 more
-
Suzhou, Jiangsu, ChinaThe First Affliated Hospital of Soochow University
Oct 3, 2022
Triple-negative Breast Cancer Trial in Shanghai (chidamide, camrelizumab, carboplatin)
Not yet recruiting
- Triple-negative Breast Cancer
- chidamide
- +3 more
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Jun 25, 2022
Leukemia, Myeloid, Acute Trial in Guanzhou (Azacitidine, Chidamide)
Recruiting
- Leukemia, Myeloid, Acute
- Azacitidine
- Chidamide
-
Guanzhou, Guandong, ChinaNanfang Hospital of Southern Medical University
Mar 6, 2022
Advanced Breast Cancer Trial in Shenyang (Chidamide, Fulvestrant)
Recruiting
- Advanced Breast Cancer
- Chidamide
- Fulvestrant
-
Shenyang, Liaoning, ChinaLiangning Tumor Hospital &Institute
Sep 8, 2021
Peripheral T-Cell Lymphoma Trial in Zhengzhou (Parsaclisib, Chidamide)
Not yet recruiting
- Peripheral T-Cell Lymphoma
- Parsaclisib
- Chidamide
-
Zhengzhou, Henan, ChinaHenan Cancer Hospital/The affiliated Cancer Hospital of ZhengZho
Dec 26, 2021
Neuroendocrine Tumors, Neuroendocrine Tumor Grade 3, Neuroendocrine Carcinoma Trial in Xiamen, Harbin (Chidamide, Sintilimab)
Recruiting
- Neuroendocrine Tumors
- +3 more
- Chidamide
- Sintilimab
-
Xiamen, Fujian, China
- +1 more
Nov 22, 2021
Peripheral T-cell Lymphoma Targeted Therapy Trial in Tianjin (Azacitidine, Chidamide, Cyclophosphamide)
Enrolling by invitation
- Peripheral T-cell Lymphoma Targeted Therapy
- Azacitidine
- +5 more
-
Tianjin, Tianjin, ChinaTianjin Medical University Cancer Insititute & Hospital
Jan 9, 2023
Neuroendocrine Tumors, Neuroendocrine Carcinoma Trial in Beijing, Xiamen, Harbin (Chidamide, Etoposide + Cisplatin/Carboplatin)
Recruiting
- Neuroendocrine Tumors
- Neuroendocrine Carcinoma
- Chidamide
- Etoposide + Cisplatin/Carboplatin
-
Beijing, Beijing, China
- +2 more
Nov 2, 2021
Non Hodgkin's Lymphoma Trial in China (Chidamide, Fludarabine and cyclophosphamide, Anti-CD19 CAR-T cells)
Recruiting
- Non Hodgkin's Lymphoma
- Chidamide
- +2 more
-
Beijing, Beijing, China
- +12 more
Jun 9, 2022
Non Small Cell Lung Cancer Trial in China (Chidamide, Envafolimab)
Recruiting
- Non Small Cell Lung Cancer
- Chidamide
- Envafolimab
-
Hefei, Anhui, China
- +11 more
Jan 17, 2022
Breast Cancer Trial in China (Chidamide, exemestane, )
Completed
- Breast Cancer
- Chidamide
- +2 more
-
Hefei, Anhui, China
- +21 more
Jan 10, 2022